ARMAGEN TECHNOLOGIES, INC.

Address

26679 Agoura Rd., #100
CALABASAS, CA, 91302-3811

http://www.armagen.com

Information

DUNS: 137142589
# of Employees: 9

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Sulfamidase Brain Drug Delivery in Sanfilippo Syndrome

    Amount: $1,033,433.00

    DESCRIPTION provided by applicant Type IIIA Mucopolysaccharidosis MPS also known as Sanfilippo A syndrome is a genetic disease that affects the lysosomal enzyme N sulfoglucosamine sulfohydrola ...

    SBIRPhase II2015Department of Health and Human Services
  2. Sulfamidase Brain Drug Delivery in Sanfilippo Syndrome

    Amount: $152,138.00

    DESCRIPTION (provided by applicant): Mucopolysaccharidosis (MPS) Type IIIA, also called Sanfilippo A syndrome, is a genetic disease caused by mutations in the gene encoding the lysosomal enzyme, N-su ...

    SBIRPhase I2014Department of Health and Human Services
  3. Manufacturing of Trojan Horse-TNFR Decoy Receptor Fusion Protein

    Amount: $981,134.00

    DESCRIPTION (provided by applicant): Tumor necrosis factor (TNF)-alpha plays a pro-inflammatory role in aging-related neurodegenerative diseases, such as Alzheimer's disease or Parkinson's ...

    SBIRPhase II2013Department of Health and Human Services
  4. Metachromatic Leukodystrophy Enzyme Drug Development

    Amount: $999,645.00

    DESCRIPTION (provided by applicant): Metachromatic Leukodystrophy or MLD, is a genetic disease that affects the lysosomal enzyme, arylsulfatase A (ASA). People born with MLD develop extensive lysosoma ...

    SBIRPhase II2013Department of Health and Human Services
  5. Enzyme replacement therapy of the brain in Mucopolysaccharidosis Type II

    Amount: $1,052,435.00

    DESCRIPTION (provided by applicant): Type II Mucopolysaccharidosis (MPS), also known as Hunter's syndrome, is a genetic disease that affects the lysosomal enzyme, iduronate-2-sulfatase (IDS). Con ...

    SBIRPhase II2012Department of Health and Human Services
  6. Manufacturing of Trojan Horse-TNFR Decoy Receptor Fusion Protein

    Amount: $148,530.00

    DESCRIPTION (provided by applicant): Tumor necrosis factor (TNF)- plays a pro-inflammatory role in brain diseases. The biologic TNF inhibitors (TNFI), such as the TNF decoy receptor cannot be develop ...

    SBIRPhase I2012Department of Health and Human Services
  7. Metachromatic Leukodystrophy Enzyme Drug Development

    Amount: $156,555.00

    DESCRIPTION (provided by applicant): Metachromatic leukodystrophy (MLD) is an genetic disease caused by mutations in the gene encoding the lysosomal enzyme, arylsulfatase A (ASA). Symptoms including n ...

    SBIRPhase I2012Department of Health and Human Services
  8. Enzyme replacement therapy of the brain in Mucopolysaccharidosis Type II

    Amount: $111,214.00

    DESCRIPTION (provided by applicant): Type II Mucopolysaccharidosis (MPS), also known as Hunter's syndrome, is an genetic disease that affects the lysosomal enzyme, iduronate-2-sulfatase (IDS). C ...

    SBIRPhase I2011Department of Health and Human Services
  9. Re-Engineering Blood-Borne Erythropoietin for Targeted Delivery

    Amount: $149,800.00

    DESCRIPTION (provided by applicant): Erythropoietin (EPO) is a potential new pharmaceutical to treat vascular disease of the brain, including stroke. However, EPO is a large molecule pharmaceutical th ...

    SBIRPhase I2011Department of Health and Human Services
  10. Bioengineering of a New Antibody Drug Delivery Technology

    Amount: $849,582.00

    DESCRIPTION (provided by applicant): Monoclonal antibodies (MAb) are potential new therapeutics for many brain diseases, including Alzheimer's disease (AD), Parkinson's disease, mad cow dise ...

    SBIRPhase II2011Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government